Form 4: Milestone Scientific Director Michael McGeehan Acquires Shares as Part of Annual Fee

Director Michael McGeehan acquired 123,560 shares of Milestone Scientific Inc. as part of his annual director's fee.

Summary

• On August 28, 2024, Michael McGeehan, a director of Milestone Scientific Inc., acquired 123,560 shares of common stock at a price of $0.89 per share.
• This acquisition was part of the annual fee paid to non-employee directors, totaling $100,000, payable in restricted shares.
• The shares vest over time, with one-fourth vesting immediately upon grant and the remaining balance vesting in equal tranches on October 1, 2024, January 1, 2025, and April 1, 2025.
• Following the transaction, McGeehan directly owns 596,482 shares of Milestone Scientific Inc.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, indicating a stable and expected corporate governance practice. It's neither overwhelmingly positive nor negative.

Positives

• The acquisition of shares by a director demonstrates alignment with shareholder interests.
• The vesting schedule incentivizes long-term commitment from the director.

Industry Context

Director compensation in the form of equity is a common practice to align the interests of board members with those of shareholders. The vesting schedule is a standard mechanism to ensure continued service and commitment.

Comparison to Industry Standards

• Equity compensation for board members is a common practice across various industries.
• Companies like Stryker (SYK) and Medtronic (MDT) also use restricted stock units (RSUs) as part of their director compensation packages.
• The vesting schedules are generally aligned with industry standards, typically ranging from one to three years.

Stakeholder Impact

• The transaction signals to shareholders that the director's interests are aligned with theirs.
• Employees may view this as a sign of stability and commitment from the board.

Key Dates